Philippe Lucas1,2,3, Susan Boyd4, M-J Milloy5,6, Zach Walsh7,8. 1. Social Dimensions of Health, University of Victoria, Victoria, BC, Canada. 2. Canadian Institute for Substance Use Research, Victoria, BC, Canada. 3. Tilray, Nanaimo, BC, Canada. 4. Faculty of Human and Social Development, School of Public Health and Social Policy, University of Victoria, Victoria, BC, Canada. 5. Faculty of Medicine, University of British Columbia, St. Paul's Hospital, Vancouver, BC, Canada. 6. British Columbia Centre on Substance Use, Vancouver, BC, Canada. 7. Department of Psychology, University of British Columbia, Okanagan, Kelowna, BC, Canada. 8. Centre for the Advancement of Psychological Science and Law, University of British Columbia, Okanagan, Kelowna, BC, Canada.
Abstract
OBJECTIVES: This article presents findings from a large prospective examination of Canadian medical cannabis patients, with a focus on the impacts of cannabis on prescription opioid use and quality of life over a 6-month period. METHODS: The Tilray Observational Patient Study took place at 21 medical clinics throughout Canada. This analysis includes 1,145 patients who had at least one postbaseline visit, with follow-up at 1, 3, and 6 months. Instruments included a comprehensive cannabis use inventory, the World Health Organization Quality of Life Short Form (WHOQOL-BREF), and a detailed prescription drug questionnaire. RESULTS: Participants were 57.6% female, with a median age of 52 years. Baseline opioid use was reported by 28% of participants, dropping to 11% at 6 months. Daily opioid use went from 152 mg morphine milligram equivalent (MME) at baseline to 32.2 mg MME at 6 months, a 78% reduction in mean opioid dosage. Similar reductions were also seen in the other four primary prescription drug classes identified by participants, and statistically significant improvements were reported in all four domains of the WHOQOL-BREF. CONCLUSIONS: This study provides an individual-level perspective of cannabis substitution for opioids and other prescription drugs, as well as associated improvement in quality of life over 6 months. The high rate of cannabis use for chronic pain and the subsequent reductions in opioid use suggest that cannabis may play a harm reduction role in the opioid overdose crisis, potentially improving the quality of life of patients and overall public health.
OBJECTIVES: This article presents findings from a large prospective examination of Canadian medical cannabis patients, with a focus on the impacts of cannabis on prescription opioid use and quality of life over a 6-month period. METHODS: The Tilray Observational Patient Study took place at 21 medical clinics throughout Canada. This analysis includes 1,145 patients who had at least one postbaseline visit, with follow-up at 1, 3, and 6 months. Instruments included a comprehensive cannabis use inventory, the World Health Organization Quality of Life Short Form (WHOQOL-BREF), and a detailed prescription drug questionnaire. RESULTS: Participants were 57.6% female, with a median age of 52 years. Baseline opioid use was reported by 28% of participants, dropping to 11% at 6 months. Daily opioid use went from 152 mg morphine milligram equivalent (MME) at baseline to 32.2 mg MME at 6 months, a 78% reduction in mean opioid dosage. Similar reductions were also seen in the other four primary prescription drug classes identified by participants, and statistically significant improvements were reported in all four domains of the WHOQOL-BREF. CONCLUSIONS: This study provides an individual-level perspective of cannabis substitution for opioids and other prescription drugs, as well as associated improvement in quality of life over 6 months. The high rate of cannabis use for chronic pain and the subsequent reductions in opioid use suggest that cannabis may play a harm reduction role in the opioid overdose crisis, potentially improving the quality of life of patients and overall public health.
Authors: Andrew Kolodny; David T Courtwright; Catherine S Hwang; Peter Kreiner; John L Eadie; Thomas W Clark; G Caleb Alexander Journal: Annu Rev Public Health Date: 2015-01-12 Impact factor: 21.981
Authors: Hudson Reddon; Kora DeBeck; Maria Eugenia Socias; Huiru Dong; Evan Wood; Julio Montaner; Thomas Kerr; Michael-John Milloy Journal: Drug Alcohol Rev Date: 2018-02-12
Authors: Mia Hashibe; Hal Morgenstern; Yan Cui; Donald P Tashkin; Zuo-Feng Zhang; Wendy Cozen; Thomas M Mack; Sander Greenland Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-10 Impact factor: 4.254
Authors: Zach Walsh; Robert Callaway; Lynne Belle-Isle; Rielle Capler; Robert Kay; Philippe Lucas; Susan Holtzman Journal: Int J Drug Policy Date: 2013-09-09
Authors: Sara J Hyland; Kara K Brockhaus; William R Vincent; Nicole Z Spence; Michelle M Lucki; Michael J Howkins; Robert K Cleary Journal: Healthcare (Basel) Date: 2021-03-16
Authors: Margot Gunning; Ari D Rotenberg; Lauren E Kelly; Bruce Crooks; Sapna Oberoi; Adam L Rapoport; S Rod Rassekh; Judy Illes Journal: CMAJ Open Date: 2022-03-15
Authors: Kevin F Boehnke; Laura Yakas; J Ryan Scott; Melissa DeJonckheere; Evangelos Litinas; Suzanne Sisley; Daniel J Clauw; David A Williams; Jenna McAfee Journal: J Cannabis Res Date: 2022-01-11
Authors: Nicholas Avery; Amy G McNeilage; Fiona Stanaway; Claire E Ashton-James; Fiona M Blyth; Rebecca Martin; Ali Gholamrezaei; Paul Glare Journal: BMJ Date: 2022-04-04